시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 전포도막염 치료 시장 보고서(2025년)
Panuveitis Treatment Global Market Report 2025
상품코드 : 1825490
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,457,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,334,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,211,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

전포도막염 치료 시장의 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 연평균 복합 성장률(CAGR) 9.3%로 62억 1,000만 달러로 성장할 전망입니다. 예측기간의 성장은 개인화된 의료 접근법, 새로운 치료법, 환자 중심의 의료에 대한 주력, 세계적인 건강 대처, 정밀의료에 대한 대처, 헬스케어 정책의 변화 등에 기인할 것으로 전망됩니다. 예측기간의 주요 동향으로는 시너지 효과를 노린 병용요법, 원격의료와 원격 모니터링, 영상기술의 진보, 인공지능의 통합, 세계 공동연구 등이 있습니다.

향후 5년간의 예측 성장률 9.3%는 과거 예측에서 0.2% 소폭 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세장벽은 스위스나 아일랜드에서 조달되는 면역억제 생물제제와 코르티코스테로이드 임플란트의 비용을 상승시킴으로써 미국에 지장을 초래할 것으로 예상되며, 그 결과 시력 회복 치료가 지연되고 안과 지출이 증가합니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 예상됩니다.

눈 관련 질환의 유병률 증가는 향후 전포도막염 치료 시장의 성장을 가속할 것으로 예측됩니다. 눈 관련 질환은 눈 질환 또는 안병이라고도 불리며 눈의 건강과 기능에 영향을 미치는 병리입니다. 전포도막염 치료는 염증을 억제하고, 합병증을 예방하며, 안질환으로 고통받는 환자의 삶의 질을 향상시킵니다. 예를 들어, 미국 공중보건기구인 질병관리예방센터(CDC)에 따르면 2022년 12월에는 40세 이상의 미국인 중 2,050만 명이 적어도 하나의 백내장을 가진 것으로 나타났습니다. 또한 2028년까지 약 3천만 명이 백내장 안질환을 앓을 것으로 예측되고 있습니다. 따라서 눈과 관련된 질병의 유병률 증가가 전포도막염 치료 시장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Panuveitis represents a severe inflammation affecting all layers of the eye's uvea, encompassing the iris, ciliary body, and choroid, with potential repercussions on the retina, vitreous humor, optic nerve, or eye lens. Timely and effective panuveitis treatment is crucial to mitigate inflammation, alleviate symptoms, and prevent vision loss or complications associated with the condition.

The primary drug classes employed in panuveitis treatment include anti-inflammatory medications, antimicrobial drugs, immunotherapy, and targeted therapies. Anti-inflammatory agents are substances or treatments specifically designed to reduce inflammation within the body. These therapeutic interventions can be administered through various routes, including oral and topical applications. Panuveitis treatments are utilized by diverse end-users such as hospitals, home care services, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The panuveitis treatment market research report is one of a series of new reports from The Business Research Company that provides panuveitis treatment market statistics, including panuveitis treatment industry global market size, regional shares, competitors with a panuveitis treatment market share, detailed panuveitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the panuveitis treatment industry. This panuveitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The panuveitis treatment market size has grown strongly in recent years. It will grow from $3.98 billion in 2024 to $4.35 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increased prevalence of uveitis, increased awareness and early diagnosis, improved drug delivery systems, patient advocacy initiatives, government support and regulatory approvals.

The panuveitis treatment market size is expected to see strong growth in the next few years. It will grow to $6.21 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to personalized medicine approaches, emerging therapeutic modalities, focus on patient-centric care, global health preparedness, precision medicine initiatives, healthcare policy changes. Major trends in the forecast period include combination therapies for synergistic effects, telemedicine and remote monitoring, advancements in imaging technologies, integration of artificial intelligence, global collaborations in research.

The forecast of 9.3% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of immunosuppressive biologics and corticosteroid implants sourced from Switzerland and Ireland, thereby delaying vision-saving treatments and elevating ophthalmology department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of eye-related diseases is expected to propel the growth of the panuveitis treatment market going forward. Eye-related diseases, also known as ocular diseases or eye conditions, are medical conditions that affect the health and function of the eyes. Panuveitis treatment reduces inflammation, prevents complications, and improves the quality of life for patients suffering from eye diseases. For instance, in December 2022, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, 20.5 million Americans over 40 had at least one cataract. Additionally, it is anticipated that approximately 30 million people will have cataract eye disease by 2028. Therefore, the increasing prevalence of eye-related diseases drives the panuveitis treatment market.

The increasing prevalence of autoimmune disorders is anticipated to drive the growth of the panuveitis treatment market in the future. The rise in autoimmune disorders can be attributed to a mix of genetic factors, environmental influences such as pollution and changes in diet, as well as greater exposure to specific infections and stressors that may lead to immune system dysregulation. These disorders are prompting advancements in panuveitis treatment by stimulating research into immune system modulation, as many panuveitis cases are associated with autoimmune activity. For example, in May 2023, the University of Oxford, a UK-based research institution, reported that autoimmune disorders impact 10% of the global population, affecting 13% of women and 7% of men. Consequently, the rising prevalence of autoimmune disorders is driving the expansion of the panuveitis treatment market.

Advancements in surgical interventions are anticipated to fuel the growth of the panuveitis treatment market in the coming years. Surgical procedures offer crucial treatment avenues for severe cases of panuveitis, addressing complications and aiding in restoring vision. These interventions encompass techniques such as vitrectomy, surgical removal of the vitreous gel in the eye, and implantation of devices or artificial intraocular lenses to manage panuveitis-related vision impairments. For example, in a clinical report published in June 2023 by the American Academy of Ophthalmology, innovative surgical approaches have shown promising outcomes in treating panuveitis complications, signifying a growing reliance on surgical interventions for managing the condition. Hence, advancements in surgical treatments are propelling the growth of the panuveitis treatment market.

Prominent enterprises engaged in the panuveitis treatment market are directing their efforts towards the development of innovative therapeutic solutions such as Xipere, aimed at providing enhanced and dependable services to their clientele. Xipere (triamcinolone acetonide) represents a corticosteroid administered via suprachoroidal injection to address macular edema induced by ocular inflammation. For instance, in February 2022, Clearside Biomedical Inc., a distinguished biopharmaceutical entity specializing in advanced drug delivery solutions for ocular diseases, introduced Xipere for treating macular edema linked to uveitis and panuveitis in the United States. Being the pioneering approved therapy containing triamcinolone acetonide, Xipere offers a preservative-free, sterile formulation designed specifically for suprachoroidal administration, utilizing Clearside's proprietary microinjector intended for the suprachoroidal space (SCS).

In July 2023, Harrow Health Inc., a US-based company, acquired Santen for an undisclosed amount. This acquisition allows Harrow to enhance its portfolio by integrating Santen's expertise in developing innovative treatments for uveitis and panuveitis. Santen Pharmaceutical Co. Ltd, based in Japan, specializes in providing treatments for panuveitis.

Major companies operating in the panuveitis treatment market report are Pfizer Inc., Johnson and Johnson Pvt. Ltd., Bausch Health Companies Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Hoffmann-La Roche Ltd., Allergan Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Ltd., Horizon Therapeutics PLC, Hikma Pharmaceuticals PLC, Santen Pharmaceutical Co. Ltd., Jubilant Life Sciences Ltd., HanAll Biopharma Inc., Xbrane Biopharma AB, Alimera Science Inc., Ocular Therapeutix Inc., EyeGate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Graybug Vision Inc., Xoma Corporation, Tarsier Pharma Ltd., Vintage Labs Pvt. Ltd., Icon Bioscience Inc., Aciont Inc., Clearside Biomedical Inc., Aldeyra Therapeutics Inc.

North America was the largest region in the panuveitis treatment market in 2024. The regions covered in the panuveitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the panuveitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Panuveitis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on panuveitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for panuveitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The panuveitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Panuveitis Treatment Market Characteristics

3. Panuveitis Treatment Market Trends And Strategies

4. Panuveitis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Panuveitis Treatment Growth Analysis And Strategic Analysis Framework

6. Panuveitis Treatment Market Segmentation

7. Panuveitis Treatment Market Regional And Country Analysis

8. Asia-Pacific Panuveitis Treatment Market

9. China Panuveitis Treatment Market

10. India Panuveitis Treatment Market

11. Japan Panuveitis Treatment Market

12. Australia Panuveitis Treatment Market

13. Indonesia Panuveitis Treatment Market

14. South Korea Panuveitis Treatment Market

15. Western Europe Panuveitis Treatment Market

16. UK Panuveitis Treatment Market

17. Germany Panuveitis Treatment Market

18. France Panuveitis Treatment Market

19. Italy Panuveitis Treatment Market

20. Spain Panuveitis Treatment Market

21. Eastern Europe Panuveitis Treatment Market

22. Russia Panuveitis Treatment Market

23. North America Panuveitis Treatment Market

24. USA Panuveitis Treatment Market

25. Canada Panuveitis Treatment Market

26. South America Panuveitis Treatment Market

27. Brazil Panuveitis Treatment Market

28. Middle East Panuveitis Treatment Market

29. Africa Panuveitis Treatment Market

30. Panuveitis Treatment Market Competitive Landscape And Company Profiles

31. Panuveitis Treatment Market Other Major And Innovative Companies

32. Global Panuveitis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Panuveitis Treatment Market

34. Recent Developments In The Panuveitis Treatment Market

35. Panuveitis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기